Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors
暂无分享,去创建一个
J. Doroshow | A. Chen | E. Polley | L. Neckers | J. Trepel | L. Chang | S. Kummar | J. Lyons | Min-Jung Lee | Sunmin Lee | R. Bishop | K. Do | R. Kinders | G. Speranza | J. Collins | Weimin Zhu | Larry Phillips | W. Jeong | Ramya Antony